- Home
- ERNA vs INTS Comparison
ERNA vs INTS Comparison
Compare ERNA & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- INTS
- Stock Information
- Founded
- ERNA 2018
- INTS 2012
- Country
- ERNA United States
- INTS United States
- Employees
- ERNA N/A
- INTS N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ERNA Health Care
- INTS Health Care
- Exchange
- ERNA Nasdaq
- INTS Nasdaq
- Market Cap
- ERNA 10.2M
- INTS 12.2M
- IPO Year
- ERNA N/A
- INTS 2023
- Fundamental
- Price
- ERNA $1.29
- INTS $0.28
- Analyst Decision
- ERNA
- INTS Strong Buy
- Analyst Count
- ERNA 0
- INTS 4
- Target Price
- ERNA N/A
- INTS $4.50
- AVG Volume (30 Days)
- ERNA 162.4K
- INTS 5.1M
- Earning Date
- ERNA 11-11-2025
- INTS 11-12-2025
- Dividend Yield
- ERNA N/A
- INTS N/A
- EPS Growth
- ERNA N/A
- INTS N/A
- EPS
- ERNA N/A
- INTS N/A
- Revenue
- ERNA $488,000.00
- INTS N/A
- Revenue This Year
- ERNA N/A
- INTS N/A
- Revenue Next Year
- ERNA N/A
- INTS N/A
- P/E Ratio
- ERNA N/A
- INTS N/A
- Revenue Growth
- ERNA 201.24
- INTS N/A
- 52 Week Low
- ERNA $1.09
- INTS $0.19
- 52 Week High
- ERNA $18.75
- INTS $3.53
- Technical
- Relative Strength Index (RSI)
- ERNA 49.69
- INTS 51.05
- Support Level
- ERNA $1.25
- INTS $0.27
- Resistance Level
- ERNA $1.38
- INTS $0.37
- Average True Range (ATR)
- ERNA 0.08
- INTS 0.03
- MACD
- ERNA 0.02
- INTS 0.01
- Stochastic Oscillator
- ERNA 63.47
- INTS 39.81
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.